CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Galera Therapeutics, Inc. - GRTX CFD

    0.1715
    1.54%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.0113
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026151 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026151%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003929 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003929%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Galera Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 0.1689
    Open* 0.17
    1-Year Change* -87.86%
    Day's Range* 0.167 - 0.1736
    52 wk Range 0.20-3.59
    Average Volume (10 days) 1.43M
    Average Volume (3 months) 52.63M
    Market Cap 8.95M
    P/E Ratio -100.00K
    Shares Outstanding 43.93M
    Revenue N/A
    EPS -2.16
    Dividend (Yield %) N/A
    Beta 1.90
    Next Earnings Date Nov 7, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Sep 22, 2023 0.1715 0.0014 0.82% 0.1701 0.1741 0.1670
    Sep 21, 2023 0.1689 -0.0178 -9.53% 0.1867 0.1867 0.1675
    Sep 20, 2023 0.1843 -0.0202 -9.88% 0.2045 0.2045 0.1807
    Sep 19, 2023 0.1980 0.0035 1.80% 0.1945 0.2280 0.1945
    Sep 18, 2023 0.1841 -0.0019 -1.02% 0.1860 0.1878 0.1831
    Sep 15, 2023 0.1816 -0.0044 -2.37% 0.1860 0.1876 0.1805
    Sep 14, 2023 0.1848 -0.0012 -0.65% 0.1860 0.1921 0.1845
    Sep 13, 2023 0.1885 0.0019 1.02% 0.1866 0.1948 0.1855
    Sep 12, 2023 0.1878 -0.0004 -0.21% 0.1882 0.1933 0.1845
    Sep 11, 2023 0.1880 -0.0022 -1.16% 0.1902 0.1941 0.1856
    Sep 4, 2023 2.1500 0.0000 0.00% 2.1500 2.1500 2.1500
    Aug 22, 2023 2.1500 0.0000 0.00% 2.1500 2.1500 2.1500
    Aug 9, 2023 2.1500 0.0700 3.37% 2.0800 2.2400 2.0000
    Aug 8, 2023 2.0400 0.1000 5.15% 1.9400 2.0700 1.8900
    Aug 7, 2023 2.1000 -0.1000 -4.55% 2.2000 2.2000 2.0500
    Aug 4, 2023 2.1600 -0.0200 -0.92% 2.1800 2.2600 2.0700
    Aug 3, 2023 2.1600 0.1400 6.93% 2.0200 2.3200 2.0000
    Aug 2, 2023 2.0600 -0.1200 -5.50% 2.1800 2.1800 2.0300
    Aug 1, 2023 2.1900 -0.2000 -8.37% 2.3900 2.4000 2.1700
    Jul 31, 2023 2.3900 -0.2388 -9.08% 2.6288 2.6387 2.3757

    Galera Therapeutics, Inc. Events

    Time (UTC) Country Event
    Tuesday, November 7, 2023

    Time (UTC)

    13:30

    Country

    US

    Event

    Q3 2023 Galera Therapeutics Inc Earnings Release
    Q3 2023 Galera Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    Wednesday, March 6, 2024

    Time (UTC)

    13:30

    Country

    US

    Event

    Q4 2023 Galera Therapeutics Inc Earnings Release
    Q4 2023 Galera Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 0 0 0
    Total Operating Expense 51.226 73.368 70.553 50.691 24.255
    Selling/General/Admin. Expenses, Total 20.214 20.951 15.708 8.358 5.592
    Research & Development 31.012 52.417 54.845 42.333 18.663
    Operating Income -51.226 -73.368 -70.553 -50.691 -24.255
    Interest Income (Expense), Net Non-Operating -11.066 -7.166 -3.681 -1.248 0.356
    Net Income Before Taxes -62.292 -80.534 -74.234 -51.939 -23.899
    Net Income After Taxes -62.222 -80.534 -74.218 -51.93 -23.676
    Net Income Before Extra. Items -62.222 -80.534 -74.218 -51.93 -23.676
    Net Income -62.222 -80.534 -74.218 -51.93 -23.676
    Total Adjustments to Net Income -7.176 -5.91
    Income Available to Common Excl. Extra. Items -62.222 -80.534 -74.218 -59.106 -29.586
    Income Available to Common Incl. Extra. Items -62.222 -80.534 -74.218 -59.106 -29.586
    Diluted Net Income -62.222 -80.534 -74.218 -59.106 -29.586
    Diluted Weighted Average Shares 27.0867 25.7895 24.8698 24.8116 24.3621
    Diluted EPS Excluding Extraordinary Items -2.29715 -3.12275 -2.98427 -2.3822 -1.21443
    Dividends per Share - Common Stock Primary Issue 0
    Diluted Normalized EPS -2.29715 -3.12275 -2.98427 -2.3822 -1.21443
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Total Operating Expense 16.807 13.881 13.158 12.959 11.929
    Selling/General/Admin. Expenses, Total 9.246 6.609 5.021 4.853 5.293
    Research & Development 7.561 7.272 8.137 8.106 6.636
    Operating Income -16.807 -13.881 -13.158 -12.959 -11.929
    Interest Income (Expense), Net Non-Operating -3.905 -3.829 -3.073 -3.075 -2.629
    Net Income Before Taxes -20.712 -17.71 -16.258 -16.033 -14.558
    Net Income After Taxes -20.712 -17.71 -16.188 -16.033 -14.558
    Net Income Before Extra. Items -20.712 -17.71 -16.188 -16.033 -14.558
    Net Income -20.712 -17.71 -16.188 -16.033 -14.558
    Income Available to Common Excl. Extra. Items -20.712 -17.71 -16.188 -16.033 -14.558
    Income Available to Common Incl. Extra. Items -20.712 -17.71 -16.188 -16.033 -14.558
    Diluted Net Income -20.712 -17.71 -16.188 -16.033 -14.558
    Diluted Weighted Average Shares 42.917 35.1961 27.9516 26.8235 26.8213
    Diluted EPS Excluding Extraordinary Items -0.48261 -0.50318 -0.57914 -0.59772 -0.54278
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.48261 -0.50318 -0.57852 -0.59776 -0.54278
    Gain (Loss) on Sale of Assets -0.027 0.001
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 38.535 77.392 77.929 117.57 83.852
    Cash and Short Term Investments 31.597 71.217 72.776 112.29 81.517
    Cash & Equivalents 4.266 19.859 15.872 18.356 14.811
    Short Term Investments 27.331 51.358 56.904 93.934 66.706
    Total Receivables, Net 0 0.87
    Prepaid Expenses 3.646 6.175 5.153 5.28 1.465
    Total Assets 44.036 83.311 84.098 123.376 88.056
    Property/Plant/Equipment, Total - Net 0.481 0.823 1.553 1.749 0.568
    Property/Plant/Equipment, Total - Gross 2.182 2.41 2.362 2.19 0.775
    Accumulated Depreciation, Total -1.701 -1.587 -0.809 -0.441 -0.207
    Goodwill, Net 0.881 0.881 0.881 0.881 0.881
    Intangibles, Net 2.258 2.258 2.258 2.258 2.258
    Other Long Term Assets, Total 1.881 1.957 1.477 0.918 0.497
    Total Current Liabilities 13.379 12.935 13.968 9.694 6.444
    Accounts Payable 3.581 5.044 5.146 3.945 3.867
    Accrued Expenses 9.798 7.891 8.822 5.749 2.577
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 153.217 141.315 77.98 53.768 26.974
    Total Long Term Debt 139.635 128.063 63.369 43.251 20.22
    Long Term Debt 139.635 128.063 63.369 43.251 20.22
    Deferred Income Tax 0.203 0.273 0.273 0.289 0.298
    Other Liabilities, Total 0 0.044 0.37 0.534 0.012
    Total Equity -109.181 -58.004 6.118 69.608 61.082
    Redeemable Preferred Stock 0
    Common Stock 0.028 0.026 0.025 0.025 0
    Retained Earnings (Accumulated Deficit) -378.324 -316.102 -235.568 -161.35 -104.823
    Other Equity, Total -0.022 -0.014 0.012 0.038 0.003
    Total Liabilities & Shareholders’ Equity 44.036 83.311 84.098 123.376 88.056
    Total Common Shares Outstanding 28.5101 26.4588 24.9761 24.8116 24.3621
    Preferred Stock - Non Redeemable, Net 165.902
    Additional Paid-In Capital 269.137 258.086 241.649 230.895
    Other Current Assets, Total 3.292
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 54.243 38.535 44.917 55.188 65.276
    Cash and Short Term Investments 47.751 31.597 42.769 52.007 60.947
    Cash & Equivalents 25.687 4.266 12.73 17.376 19.645
    Short Term Investments 22.064 27.331 30.039 34.631 41.302
    Prepaid Expenses 3.2 3.646 2.098 3.181 4.329
    Total Assets 59.714 44.036 50.713 61.078 71.099
    Property/Plant/Equipment, Total - Net 0.418 0.481 0.57 0.654 0.738
    Property/Plant/Equipment, Total - Gross 1.869 2.182 2.246 2.302 2.357
    Accumulated Depreciation, Total -1.451 -1.701 -1.676 -1.648 -1.619
    Goodwill, Net 0.881 0.881 0.881 0.881 0.881
    Intangibles, Net 2.258 2.258 2.258 2.258 2.258
    Other Long Term Assets, Total 1.914 1.881 2.087 2.097 1.946
    Total Current Liabilities 13.266 13.379 11.632 10.986 10.931
    Accounts Payable 5.937 3.581 3.591 3.588 4.131
    Accrued Expenses 7.329 9.798 8.041 7.398 6.8
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 157.327 153.217 148.215 144.324 141.57
    Total Long Term Debt 143.858 139.635 136.31 133.065 130.366
    Long Term Debt 143.858 139.635 136.31 133.065 130.366
    Deferred Income Tax 0.203 0.203 0.273 0.273 0.273
    Other Liabilities, Total 0 0 0 0
    Total Equity -97.613 -109.181 -97.502 -83.246 -70.471
    Common Stock 0.043 0.028 0.027 0.027 0.027
    Additional Paid-In Capital 298.362 269.137 264.7 262.94 261.108
    Retained Earnings (Accumulated Deficit) -396.034 -378.324 -362.136 -346.103 -331.545
    Other Equity, Total 0.016 -0.022 -0.093 -0.11 -0.061
    Total Liabilities & Shareholders’ Equity 59.714 44.036 50.713 61.078 71.099
    Total Common Shares Outstanding 42.9068 28.5101 26.4388 26.8216 26.8194
    Total Receivables, Net
    Redeemable Preferred Stock 0
    Other Current Assets, Total 3.292 3.292 0.05
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -62.222 -80.534 -74.218 -51.93 -23.676
    Cash From Operating Activities -43.426 -67.958 -59.537 -46.661 -22.166
    Cash From Operating Activities 0.114 0.778 0.368 0.267 0.127
    Deferred Taxes -0.07 0 -0.016 -0.009 -0.223
    Non-Cash Items 15.493 14.425 10.416 5.666 1.083
    Changes in Working Capital 3.259 -2.627 3.913 -0.655 0.523
    Cash From Investing Activities 23.994 5.238 36.547 -27.825 -59.036
    Capital Expenditures -0.025 -0.283 -0.457 -0.633 -0.347
    Other Investing Cash Flow Items, Total 24.019 5.521 37.004 -27.192 -58.689
    Cash From Financing Activities 3.889 66.707 20.506 78.031 89.844
    Financing Cash Flow Items 0 69.844
    Issuance (Retirement) of Debt, Net 0 57.5 20 20 20
    Net Change in Cash -15.543 3.987 -2.484 3.545 8.642
    Issuance (Retirement) of Stock, Net 3.889 9.207 0.506 58.031
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -17.71 -62.222 -46.034 -30.001 -15.443
    Cash From Operating Activities -11.666 -43.426 -29.481 -20.271 -11.385
    Cash From Operating Activities 0.02 0.114 0.088 0.061 0.031
    Non-Cash Items 5.681 15.493 13.675 8.68 4.151
    Changes in Working Capital 0.343 3.259 2.79 0.989 -0.124
    Cash From Investing Activities 5.305 23.994 21.215 16.611 9.996
    Capital Expenditures 0 -0.025 -0.025 -0.02 -0.013
    Other Investing Cash Flow Items, Total 5.305 24.019 21.24 16.631 10.009
    Cash From Financing Activities 27.782 3.889 1.187 1.177 1.175
    Issuance (Retirement) of Stock, Net 27.782 3.889 1.187 1.177 1.175
    Issuance (Retirement) of Debt, Net 0 0 0
    Net Change in Cash 21.421 -15.543 -7.079 -2.483 -0.214
    Deferred Taxes -0.07

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Galera Therapeutics, Inc. Company profile

    About Galera Therapeutics Inc

    Galera Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing and commercializing a pipeline of therapeutics to transform radiotherapy in cancer. The Company's lead product candidate, avasopasem manganese (GC4419), is a potent and selective small molecule dismutase mimetic, which is developed for the reduction of severe oral mucositis (SOM). It is also developing a second dismutase mimetic product candidate, GC4711, to increase the anti-cancer efficacy of stereotactic body radiation therapy (SBRT). It is evaluating GC4419 in a Phase III registrational trial (ROMAN trial) to reduce the incidence and severity of SOM induced by radiotherapy in patients with head and neck cancer (HNC), its lead indication. The Company is also evaluating GC4711 in combination with SBRT in a Phase I/II safety and anti-cancer efficacy trial in non-small cell lung cancer and a Phase IIb trial of GC4711 in combination with SBRT in patients with pancreatic cancer.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Galera Therapeutics Inc revenues was not reported. Net loss increased 9% to $80.5M. Higher net loss reflects General and administrative - Balancing increase of 32% to $16.6M (expense), Interest expense increase of 47% to $7.2M (expense), Stock-based Compensation in SGA increase of 40% to $4.3M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$2.98 to -$3.12.

    Industry: Bio Therapeutic Drugs

    45 Liberty Blvd.
    Suite 230
    MALVERN
    PENNSYLVANIA 19355
    US

    Income Statement

    • Annual
    • Quarterly

    News

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    Cable coils near lows ahead of Fed and BoE rate decisions

    It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

    14:16, 19 September 2023

    FTSE 100 Technical Outlook - 18 September 2023

    In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

    06:55, 19 September 2023
    View of the City of London’s illuminated financial district skyline at dusk

    Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

    The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

    13:46, 15 September 2023

    People also watch

    US100

    14,710.90 Price
    +0.190% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0039%
    Overnight fee time 21:00 (UTC)
    Spread 7.0

    BTC/USD

    26,652.10 Price
    +0.030% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    XRP/USD

    0.52 Price
    +0.190% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    Oil - Crude

    90.14 Price
    +0.770% 1D Chg, %
    Long position overnight fee 0.0415%
    Short position overnight fee -0.0634%
    Overnight fee time 21:00 (UTC)
    Spread 0.030

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading